Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

The increasing availability of genotype data linked with information about drug‐response
phenotypes has enabled genomewide association studies (GWAS) that uncover genetic …

Most of the prescribing and dispensing of medicines happens in primary care.
Pharmacogenomics (PGx) is the study and clinical application of the role of genetic variation …

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly used
psychopharmaceutical treatment for major depressive disorder (MDD), but individual …

The origins of pharmacogenetics date back to the 1950s, when it was established that inter-
individual differences in drug response are partially determined by genetic factors. Since …

Cardiovascular disease remains a leading cause of both morbidity and mortality worldwide.
It is widely accepted that both concomitant medications (drug–drug interactions, DDIs) and …

Rationale: Standardized dosing of antitubercular drugs contributes to a substantial
incidence of toxicities, inadequate treatment response, and relapse, in part due to variable …

Recent breakthroughs in human genetics and in information technologies have markedly
expanded our understanding at the molecular level of the response to drugs, ie …

An individual's genetics can dramatically influence breast cancer (BC) risk. Although clinical
measures for prevention do exist, non-invasive personalized measures for reducing BC risk …

Pharmacogenetic testing in the United Kingdom's National Health Service (NHS) has
historically been reactive in nature, undertaken in the context of single gene-drug …